An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant?
L
Lauren P. Jatt
(Division of Allergy and Infectious Disease, University of Washington, Seattle)
N
Nyaradzo M. Mgodi
(University of Zimbabwe Clinical Trials Research Centre, Harare)
S
Susan P. Buchbinder
(San Francisco Department of Public Health, San Francisco)
G
Glenda E. Gray
(Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg)
J
James G. Kublin
(Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle)
Article Details
Journal
New England Journal of Medicine
Volume / Issue
Vol. 392, Issue 16
Published
April 24, 2025
Pages
1561-1563
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
ISSN: 0028-4793 Social Sciences
Authors (5)
L
Lauren P. Jatt
Division of Allergy and Infectious Disease, University of Washington, Seattle
N
Nyaradzo M. Mgodi
University of Zimbabwe Clinical Trials Research Centre, Harare
S
Susan P. Buchbinder
San Francisco Department of Public Health, San Francisco
G
Glenda E. Gray
Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg
J
James G. Kublin
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle
Related Articles from this Journal
Doctor’s Dirty Little Secret — The Cost of Silence
Tara Khan
Aug 2026
10.1056/nejmp2515506
Obstructive Hypertrophic Cardiomyopathy
Julian-Kai Nishizono, Marohito Nakata
Aug 2026
10.1056/nejmicm2603868
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Martina Schatzl, Katharina A. Mayer et al.
Jul 2026
10.1056/nejmc2603853
Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
Jerry Avorn
Jul 2026
10.1056/nejmp2604841
Precision Intensification in Metastatic Prostate Cancer
Rana R. McKay
Jul 2026
10.1056/nejme2605582